An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Puma Biotechnology, Inc. (NASDAQ: PBYI) is set to hold a conference call on May 4, 2023, at 1:30 p.m. PDT to discuss its first quarter 2023 financial results. The call can be accessed domestically at 1-877-709-8150 and internationally at 1-201-689-8354. A live webcast will also be available on Puma's website, along with a replay accessible for 90 days post-call.
As a biopharmaceutical company, Puma is focused on developing innovative cancer care therapies. Its product NERLYNX® (neratinib) has been approved for treating certain breast cancer cases. In addition, Puma has licensed the development rights for alisertib, an anti-cancer drug aimed at small cell lung cancer and breast cancer.
Positive
Focus on expanding cancer care through innovative products.
NERLYNX® has FDA approval for multiple indications.
Exclusive license for alisertib emphasizes growth potential.
Negative
None.
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at https://www.NERLYNX.com or by dialing 1-855-816-5421.
What time is the Puma Biotechnology conference call on May 4, 2023?
The Puma Biotechnology conference call is scheduled for 1:30 p.m. PDT on May 4, 2023.
How can I access the Puma Biotechnology conference call?
You can access the conference call by dialing 1-877-709-8150 domestically or 1-201-689-8354 internationally.
What is Puma Biotechnology's stock symbol?
Puma Biotechnology's stock symbol is PBYI.
What products does Puma Biotechnology focus on?
Puma Biotechnology focuses on developing and commercializing cancer care products, notably NERLYNX® and alisertib.
What are the recent developments for NERLYNX®?
NERLYNX® has FDA approval for the extended adjuvant treatment of HER2-positive breast cancer and also in combination with capecitabine for advanced cases.
